Solid tumors are dependent on angiogenesis for delivery of oxygen and nutrients required for their growth and metastasis. Tumor cells migrate into blood and lymphatic vessels and disseminate to other organs and tissues where they can originate metastatic growth.

AsclepiX platform technologies are applied to create cancer-specific anti-angiogenic and anti-lymphangiogenic nanomedicines to be used as neoadjuvant and adjuvant therapies to inhibit tumor growth and metastasis.